Preclinical development of a miR-132 inhibitor for heart failure treatment

Preclinical development of a miR-132 inhibitor for heart failure treatment

miR-132 was shown to drive pathological cardiac remodeling, a hallmark of heart failure. Here, the authors show that an antisense inhibitor of miR-132 has favourable pharmacokinetics, safety-tolerability and preclinical efficacy in mouse and porcine models of heart failure.

Guardado en:
Detalles Bibliográficos
Autores principales: Ariana Foinquinos, Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Mariann Gyöngyösi, Denise Traxler, Martin Riesenhuber, Andreas Spannbauer, Dominika Lukovic, Natalie Weber, Katrin Zlabinger, Ena Hašimbegović, Johannes Winkler, Jan Fiedler, Seema Dangwal, Martin Fischer, Jeanne de la Roche, Daniel Wojciechowski, Theresia Kraft, Rita Garamvölgyi, Sonja Neitzel, Shambhabi Chatterjee, Xiaoke Yin, Christian Bär, Manuel Mayr, Ke Xiao, Thomas Thum
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/33579ddb7f504de8ad9792e4fd12c4d2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:miR-132 was shown to drive pathological cardiac remodeling, a hallmark of heart failure. Here, the authors show that an antisense inhibitor of miR-132 has favourable pharmacokinetics, safety-tolerability and preclinical efficacy in mouse and porcine models of heart failure.

Ejemplares similares